Compare TMP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | COLL |
|---|---|---|
| Founded | 1836 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2015 |
| Metric | TMP | COLL |
|---|---|---|
| Price | $84.53 | $35.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $74.00 | $51.40 |
| AVG Volume (30 Days) | 46.3K | ★ 546.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 11.24 | 1.73 |
| Revenue | $75,742,000.00 | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $7.94 | N/A |
| P/E Ratio | ★ $7.58 | $20.60 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $56.55 | $25.87 |
| 52 Week High | $86.95 | $50.79 |
| Indicator | TMP | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 50.42 |
| Support Level | $72.14 | $34.29 |
| Resistance Level | $86.95 | $36.20 |
| Average True Range (ATR) | 1.76 | 1.07 |
| MACD | 0.89 | 0.70 |
| Stochastic Oscillator | 84.41 | 87.00 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.